Antibiotic optimization: An evaluation of patient safety and economic outcomes

Archives of Internal Medicine

Volumn 157, Issue 15, 1997, Pages 1689-1694

  Fraser, Gilles L ^a,b   Stogsdill, Patricia ^a,b   Dickens Jr , John D ^b   Wennberg, David E ^b   Smith Jr , Robert P ^a,b   Prato, B Stephen ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFOTETAN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; FLUCONAZOLE; SULTAMICILLIN; TOBRAMYCIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG SAFETY; ECONOMICS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030803871     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.15.1689     Document Type: Article

References (50)

1. Pelletier LL. Hospital usage of parenteral antimicrobial agents: a graduated review and cost containment program. Infect Control. 1985;6:226-230.
2. Dunagan WC, Woodward RS, Medoff G, et al. Antimicrobial misuse in patients with positive blood cultures. Am J Med. 1989;87:253-259.
3. Arbo MD, Snydman DR. Influence of blood culture results on antibiotic choice in the treatment of bacteremia. Arch Intern Med. 1994;154:2641-2645.
4. McGowan JE. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol. 1994;15:478-483.
5. Goldman DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA. 1996;275:234-240.
6. Hess DA, Mahoney CD, Johnson PN, Corrao WM, Fisher AE. Integration of clinical and administrative strategies to reduce expenditures for antimicrobial agents. Am J Hosp Pharm. 1990;47:585-591.
7. Himmelberg CJ, Pleasants RA, Weber DJ, et al. Use of antimicrobial drugs in adults before and after removal of a restriction policy. Am J Hosp Pharm. 1991; 48:1220-1227.
8. Maswoswe JJ, Okpara AU. Enforcing a policy for restricting antimicrobial drug use. Am J Health Syst Pharm. 1995;52:1433-1435.
9. Frighetto L, Nickoloff D, Martinusen SM, Mamdani FS, Jewesson PJ. Intravenous-to-oral stepdown program: four years of experience in a large teaching hospital. Ann Pharmacother. 1992;26:1447-1451.
10. Lee KR, Leggiadro RJ, Burch KJ. Drug use evaluation of antibiotics in a pediatric teaching hospital. Infect Control Hosp Epidemiol. 1994;15:710-712.
11. Avorn J, Soumerai SB, Taylor W, et al. Reduction of incorrect antibiotic dosing through a structured educational order form. Arch Intern Med. 1988;148:1720-1724.
12. Quintiliani R, Nightingale CH. Antimicrobials and therapeutic decision making: an historical perspective. Pharmacotherapy. 1991;11(suppl 1, pt 2):6S-13S.
13. Fletcher CV, Metzler D, Borchardt-Phelps P, Rodman JH. Patterns of antibiotic use and expenditures during 7 years at a university hospital. Pharmacotherapy. 1990;10:199-204.
14. Crowe HM, Quintiliani R. Antibiotic formulary selection. Med Clin North Am. 1995; 79:463-476.
15. Coleman RW, Rodondi LC, Kaubisch S, Granzella NB, O'Hanley PD. Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989. Am J Med. 1991;90:439-444.
16. Berman JR, Zaren FK, Rybak MJ. Pharmacy-based antimicrobial-monitoring service. Am J Hosp Pharm. 1992;49:1701-1706.
17. Schentag JJ, Ballow CH, Fritz AL, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis. 1993;16:255-264.
18. Morrell R, Wasilauskas B, Winslow R. Personal computer-based expert system for quality assurance of antimicrobial therapy. Am J Hosp Pharm. 1993;50:2067-2073.
19. Evans RS, Classen DC, Pestotnik SL, Lundsgaarde HP, Burke JP. Improving empiric antibiotic selection using computer decision support. Arch Intern Med. 1994; 154:878-884.
20. Pestotnik SL, Classon DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med. 1996;124:884-890.
21. Nightingale CH. Impact of nosocomial infections on hospital costs. Hosp Formul. 1993;28(suppl 1):51-54.
22. Fraser GL, Wennberg DE, Dickens JD, Lambrew CT. Changing physician behavior in ordering digoxin assays. Ann Pharmacother. 1996;30:449-454.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
24. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155:1273-1276.
25. Okpara AU, Maswoswe JJ, Stewart K. Criteria-based antimicrobial IV to oral conversion program. Formulary. 1995;30:343-348.
26. Maxwell M, Heaney D, Howie JG, Noble S. General practice fundholding: observations on prescribing patterns and costs using the defined daily dose method. BMJ. 1993;307:1190-1194.
27. Marr JJ, Moffet HL, Kunin CM. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America. J Infect Dis. 1988;157:869-876.
28. Cimino MA, Rotstein CM, Moser JE. Assessment of cost-effectiveness antibiotic therapy in the management of infections in cancer patients. Ann Pharmacother. 1994;28:105-111.
29. Quintiliani R, Nightingale CH, Crowe HM, et al. Strategic antibiotic decision-making at the formulary level. Rev Infect Dis. 1991;13(suppl 9):S770-S777.
30. Schentag JJ, Carr JR, Adelman MH, et al. Formulary management vs disease management. Infect Dis Clin Pract. 1996;5(suppl 1):S42-S47.
31. Greco PJ, Eisenberg JM. Changing physicians' practices. N Engl J Med. 1993; 329:1271-1272.
32. Lee TH, Pearson SD, Johnson PA, et al. Failure of information as an intervention to modify clinical management. Ann Intern Med. 1995;122:434-437.
33. Raisch DW. A model of methods for influencing prescribing, I: a review of prescribing models, persuasion theories, and administrative and educational methods. DICP Ann Pharmacother. 1990;24:417-421.
34. Raisch DW. A model of methods for influencing prescribing. II: a review of educational methods, theories of human inference, and delineation of the model. DICP Ann Pharmacother. 1990;24:537-542.
35. Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care: a critical analysis of the experimental literature. Milbank Q. 1989;67:268-317.
36. Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance. JAMA. 1995;274:700-705.
37. Chan R, Hemeryck L, O'Regan M, Clancy L, Feely F. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomized controlled trial. BMJ. 1995;310:1360-1362.
38. Craig WA, Andes DR. Parenteral versus oral antibiotic therapy. Med Clin North Am. 1995;79:497-508.
39. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med. 1991;91:462-470.
40. Amodio-Groton M, Madu A, Madu C, et al. Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: a pharmacoeconomic analysis. Ann Pharmacother. 1996;30:596-602.
41. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. Ann Surg. 1996;223: 303-315.
42. Siegel RE, Halpern NA, Almenoff PL, et al. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia. Chest. 1996;110: 965-971.
43. Cohen MR. Important news! IV route not needed to justify hospitalization for antibiotics. Hosp Pharm. 1993;28:946.
44. Soumerai SB, Lipton HL. Computer-based drug-utilization review: risk, benefit, or boondoggle? N Engl J Med. 1995;332:1641-1645.
45. Schulman KA, Rubenstein E, Abernethy DR, Seils DM, Sulmasy DP. The effect of pharmaceutical benefits managers: is it being evaluated? Ann Intern Med. 1996; 124:906-913.
46. Quintiliani R, Cooper BW, Briceland LL, Nightingale CH. Economic impact of streamlining antibiotic administration. Am J Med. 1987;82(suppl 4A):391-394.
47. Tierney WM, Miller ME, McDonald CJ. The effect on test ordering of informing physicians of the charges for outpatient diagnostic tests. N Engl J Med. 1990; 332:1499-1504.
48. Tierney WM, Miller ME, Overhage JM, McDonald CJ. Physician inpatient order writing on microcomputer workstations. JAMA. 1993;269:379-383.
49. Rind DM, Safran C, Phillips RS, et al. Effect of computer-based alerts on the treatment and outcomes of hospitalized patients. Arch Intern Med. 1994;154:1511-1517.
50. Sullivan F, Mitchell E. Has general practitioner computing made a difference to patient care? a systematic review of published reports. BMJ. 1995;311:848-852.